Safety of Celecoxib and Mupirocin in G6PD Deficiency
Both celecoxib and mupirocin ointment can be used safely in patients with G6PD deficiency—neither medication poses a significant hemolytic risk.
Celecoxib Safety Profile
Celecoxib, a COX-2 selective NSAID, is not listed among medications that cause hemolysis in G6PD-deficient patients. The comprehensive evidence review of medications and G6PD deficiency identifies only seven medications with solid evidence for prohibition: dapsone, methylene blue, nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride 1. Celecoxib does not appear on this list.
Supporting Evidence for NSAID Safety
Ibuprofen, a related NSAID, has been systematically reviewed and shown to have extremely low risk in G6PD-deficient children (approximately 1/100,000 affected children per year in population studies, and 1/100 million per year in FDA adverse reaction databases) 2
A real-world study of 31,962 G6PD-deficient patients found only 71 cases (0.2%) of major hemolysis requiring hospitalization, with 71.8% caused by fava beans, 8.5% by infection, and only 4.2% possibly medication-related (none involving NSAIDs like celecoxib) 3
One case report documented hemolysis with diclofenac sodium suppository in a G6PD-deficient patient, but this occurred in the context of concurrent infection and pyrexia, making causality unclear 4
Standard Celecoxib Precautions Apply
The FDA label for celecoxib does not mention G6PD deficiency as a contraindication or precaution 5. Standard monitoring for:
- Cardiovascular risks
- Gastrointestinal bleeding
- Renal function
- Hepatotoxicity
These apply to all patients regardless of G6PD status.
Mupirocin Ointment Safety
Mupirocin ointment is safe for topical use in G6PD-deficient patients. This topical antibiotic for skin infections has:
- No documented cases of hemolysis in the medical literature
- Minimal systemic absorption when used topically
- No listing in comprehensive G6PD medication safety reviews 1, 6
The 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline, which systematically classified medications by risk level for G6PD deficiency, does not include mupirocin among medications requiring precautions 6.
Clinical Bottom Line
Prescribe both medications with standard precautions only. The evidence demonstrates:
- No biological mechanism for either drug to cause oxidative stress leading to hemolysis
- No case reports linking either medication to hemolytic episodes in G6PD-deficient patients
- Large real-world data showing that many medications previously suspected of causing hemolysis are actually safe 3
Key Caveat
If hemolysis occurs while a G6PD-deficient patient is taking these medications, first investigate infection or fava bean ingestion as these account for >80% of hemolytic episodes 3. The medication is unlikely to be the culprit unless it belongs to the seven high-risk drugs identified above.